The Current State of Glucose Monitoring in America
Blood glucose monitoring has split into two main camps. Traditional self-monitoring blood glucose (SMBG) devices — the classic meter plus test strips — still hold roughly 60% of the U.S. market, mostly because they're cheap upfront and familiar. But continuous glucose monitors (CGM) are growing fast, with adoption climbing among both insulin users and people with Type 2 diabetes who just want better visibility into how food and exercise move their numbers.
The shift is real. Newer CGM sensors from Abbott and Dexcom now last 14 to 15 days, wear like small patches on your arm, and send readings straight to your phone. A decade ago, CGM was mostly reserved for people with Type 1 diabetes on insulin pumps. Today, you'll find fitness-minded people without diabetes using them to experiment with nutrition. That's a big cultural change from the old "poke, test, log" routine that dominated American diabetes care for years.
Where Most People Get Stuck
The frustration usually lands in three places.
Cost confusion tops the list. A CGM sensor can carry a list price of several hundred dollars for a month's supply, and branded test strips run anywhere from $60 to $150 for a box. If you have insurance, your out-of-pocket might be $0 to $75 for a 30-day supply — but if you're uninsured or underinsured, the full price hits hard. People end up rationing strips, testing less often than they should, and missing dangerous highs and lows.
Insurance jargon is a second wall. Medicare covers CGMs under Part B as durable medical equipment, but only if you take insulin or have a documented history of severe low blood sugar. Medicaid coverage varies state by state, which means two people with identical diabetes situations can face wildly different costs depending on where they live. Colorado, for instance, added CGM coverage for Medicaid members starting November 2025, but many states still lag.
Choice paralysis is the third hurdle. Between the Libre 3 Plus, Dexcom G7, Medtronic's Guardian, Eversense's implantable sensor, and a shelf full of traditional meters, picking a system feels like a research project. Most people default to whatever their doctor mentions first, which isn't always the best fit for their routine.
Comparing the Main Blood Sugar Monitor Options
| Category | Example | Wear Time | Ideal For | Strengths | Watch Out For |
|---|
| Traditional meter | Contour Next, Accu-Chek Guide | Instant reads | Occasional testing, budget-conscious users | Low upfront cost, strips widely available | Needs finger pricks, no trend data |
| CGM (patch sensor) | FreeStyle Libre 3 Plus | 15 days | People who want continuous data without finger sticks | World's smallest sensor, no overpatch, connects to major insulin pumps | Upfront cost, prescription needed |
| CGM (patch sensor) | Dexcom G7 15 Day | 15.5 days | Those wanting real-time alerts and pump integration | Industry-leading wear time, strong Medicare coverage | Slightly larger patch, overpatch often needed |
| Implantable CGM | Eversense E3 | 6 months | People who want fewer changes | Long-term wear, no weekly sensor changes | Requires in-office insertion procedure |
Making Sense of the Numbers
Let's talk money, because that's what most Americans actually lose sleep over.
If you have commercial insurance, CGM makers have worked hard to bring copays down. Abbott says most people with commercial coverage pay between $0 and $20 for Libre sensors, and if you're asked to pay more than $75 for two Libre 3 Plus sensors, their copay card program can help close the gap. Industry analysis also notes Libre's list prices run roughly 60% lower than competing CGM systems.
Medicare beneficiaries who qualify (insulin use or documented problematic lows) pay 20% coinsurance after meeting the annual Part B deductible. The 2026 Part B deductible sits at $283, so once that's met, you're responsible for about a fifth of the Medicare-approved amount. Many Medicare Advantage plans bring that down further, and most Advantage members using Libre end up paying nothing out of pocket.
For uninsured shoppers, the math changes completely. A month of CGM sensors at list price can approach several hundred dollars, which is why many uninsured patients stick with traditional meters and buy strips in bulk. Generic and store-brand strips at retailers like Walmart and CVS run noticeably cheaper than name-brand versions — a real lifeline for people paying out of pocket.
Traditional glucose meters themselves are often inexpensive, with some retailers selling starter kits at prices low enough to feel nearly promotional. The recurring strip cost is where the real expense lives, so compare strip prices per box before you commit to a meter brand.
How to Choose the Right System for You
Step one: be honest about your testing habits. If you check your sugar a few times a week and your A1C is stable, a traditional meter is plenty. If you're on insulin, have unpredictable lows, or want to understand how meals spike you, a CGM earns its keep.
Step two: check your coverage before you buy. Call your insurance or your Medicare Advantage plan and ask three questions: Is a CGM covered? Which brands are on the preferred list? What's my copay for a 30-day supply? That conversation takes ten minutes and can save you hundreds of dollars.
Step three: get a prescription conversation started. CGMs require a prescription in the U.S., so book a visit with your doctor. Bring up your testing history, any low blood sugar episodes, and ask specifically whether you qualify for CGM under Medicare's rules if you're 65 or older.
Step four: use trial resources wisely. Abbott offers a free sensor trial for people curious about Libre, with step-by-step tutorials and phone support from certified educators. Many diabetes clinics also keep demo units, so you can hold a sensor before committing.
Step five: think about the caregiver angle. If you're caring for an aging parent or a child with Type 1 diabetes, remote monitoring matters. Both the LibreLinkUp app and Dexcom's share features let family members see glucose readings in real time and set their own alerts. For families managing pediatric diabetes, that visibility is often the deciding factor.
A Word About Non-Invasive Monitoring
You've probably seen ads for watches and rings that claim to measure blood sugar without needles. Be skeptical. As of now, the FDA-approved therapeutic CGMs all use tiny sensors inserted just under the skin — the "invasive" part is a quick, nearly painless insertion. Truly non-invasive optical wearables remain in development, and most have not cleared the regulatory bar for insulin dosing decisions. If a device doesn't require a prescription and claims to replace standard monitoring, run it past your doctor before trusting its numbers.
What Most Americans End Up Choosing
The pattern that's emerged in recent years: people newly diagnosed with Type 1 diabetes, especially children, start CGM within months. Older adults with Type 2 who manage with oral medication often stay on traditional meters, partly due to insurance restrictions and partly because the interface feels unfamiliar. Vendors are responding with simpler receivers and longer-wear sensors, but the gap remains.
For most families, the sweet spot is a traditional meter as backup plus a CGM as the daily driver. If your insurance covers a CGM affordably, the trend data is genuinely life-changing — you learn how a bagel at 8 a.m. or a late workout moves your numbers, and that knowledge changes what you do next.
If coverage isn't there yet, don't write off monitoring entirely. A solid meter with bulk strips and a free logging app still beats guessing. The goal isn't the fanciest device — it's consistency. Whatever you choose, the act of checking, logging, and sharing those numbers with your care team is what moves your A1C in the right direction.
Start with a call to your insurance, a conversation with your doctor, and one honest look at how you actually live. The right monitor is the one you'll still be using six months from now.
研究の知恵